OBJECTIVE: Withaferin A, a natural withanolide, has shown anti-cancer properties in various cancers including breast cancer, but its effects in ovarian cancer remain unexplored. Notch 1 and Notch3 are critically involved in ovarian cancer progression. We decided to examine the effects of Withaferin A in ovarian carcinoma cell lines and its molecular mechanism of action including its regulation of Notch. METHODS: The effects of Withaferin A were examined in CaOV3 and SKOV3 ovarian carcinoma cell lines using MTS assay, clonogenic assay, annexin V/propidium iodide flow cytometry, and cell cycle analysis. Western analysis was conducted to examine the molecular mechanisms of action. RESULTS: Withaferin A inhibited the growth and colony formation of CaOV3 and SKOV3 cells by inducing apoptosis and cell cycle arrest. These changes correlated with down-regulation of Notch1, Notch3, cdc25C, total and phosphorylated Akt, and bcl-2 proteins. CONCLUSIONS: Withaferin A inhibits CaOV3 and SKOV3 ovarian carcinoma cell growth, at least in part by targeting Notch1 and Notch3.
OBJECTIVE:Withaferin A, a natural withanolide, has shown anti-cancer properties in various cancers including breast cancer, but its effects in ovarian cancer remain unexplored. Notch 1 and Notch3 are critically involved in ovarian cancer progression. We decided to examine the effects of Withaferin A in ovarian carcinoma cell lines and its molecular mechanism of action including its regulation of Notch. METHODS: The effects of Withaferin A were examined in CaOV3 and SKOV3 ovarian carcinoma cell lines using MTS assay, clonogenic assay, annexin V/propidium iodide flow cytometry, and cell cycle analysis. Western analysis was conducted to examine the molecular mechanisms of action. RESULTS:Withaferin A inhibited the growth and colony formation of CaOV3 and SKOV3 cells by inducing apoptosis and cell cycle arrest. These changes correlated with down-regulation of Notch1, Notch3, cdc25C, total and phosphorylated Akt, and bcl-2 proteins. CONCLUSIONS:Withaferin A inhibits CaOV3 and SKOV3 ovarian carcinoma cell growth, at least in part by targeting Notch1 and Notch3.
Authors: G B Mills; Y Lu; X Fang; H Wang; A Eder; M Mao; R Swaby; K W Cheng; D Stokoe; K Siminovitch; R Jaffe; J Gray Journal: Semin Oncol Date: 2001-10 Impact factor: 4.929
Authors: Deborah A Altomare; Hui Qin Wang; Kristine L Skele; Assunta De Rienzo; Andres J Klein-Szanto; Andrew K Godwin; Joseph R Testa Journal: Oncogene Date: 2004-07-29 Impact factor: 9.867
Authors: Olivier Meurette; Spyros Stylianou; Rebecca Rock; Giovanna M Collu; Andrew P Gilmore; Keith Brennan Journal: Cancer Res Date: 2009-06-02 Impact factor: 12.701
Authors: Merryl R Lobo; Sarah C Green; Matthias C Schabel; G Yancey Gillespie; Randall L Woltjer; Martin M Pike Journal: Neuro Oncol Date: 2013-10-03 Impact factor: 12.300
Authors: Lynda M McEvoy; Sharon A O'Toole; Cathy D Spillane; Cara M Martin; Michael F Gallagher; Britta Stordal; Gordon Blackshields; Orla Sheils; John J O'Leary Journal: BMC Cancer Date: 2015-07-25 Impact factor: 4.430